Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3092739 | 1.00 | MEN1 (0.48) | MEN1CYP2C19KMT2ATSHRSLC6A2 | |
| SCHEMBL877724 | 1.00 | MEN1 (0.48) | MEN1CYP2C19KMT2ATSHRSLC6A2 | |
| SCHEMBL3092749 | 1.00 | MEN1 (0.48) | MEN1CYP2C19KMT2ATSHRSLC6A2 | |
| SCHEMBL15436881 | 1.00 | MEN1 (0.48) | MEN1CYP2C19KMT2ATSHRSLC6A2 | |
| SCHEMBL15436882 | 1.00 | MEN1 (0.48) | MEN1CYP2C19KMT2ATSHRSLC6A2 | |
| SCHEMBL13356510 | 0.84 | MEN1 (0.48) | MEN1CYP2C19KMT2ATSHRSLC6A2 | |
| SCHEMBL3090030 | 0.78 | CYP2C19 (0.48) | MEN1CYP2C19KMT2ATSHRSLC6A2 | |
| SCHEMBL11892313 | 0.78 | CYP2C19 (0.48) | MEN1CYP2C19KMT2ATSHRSLC6A2 | |
| SCHEMBL12228274 | 0.78 | CYP2C19 (0.48) | MEN1CYP2C19KMT2ATSHRSLC6A2 | |
| SCHEMBL10484173 | 0.78 | KCNA4 (0.41) | MEN1CYP2C19KMT2AEPHX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780787-B2 | Method for conversion of diols to olefin products | UT-BATTELLE, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230242464-A1 | METHOD FOR CONVERSION OF DIOLS TO OLEFIN PRODUCTS | UT BATTELLE LLC (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2022007838-A1 | METHOD FOR PREPARING GLUCOPYRANOSYL DERIVATIVES AND INTERMEDIATES THEREOF | DONGGUAN HEC NEW DRUG R & D CO., LTD. (CN) | 2022-01-13 | — | — | WO | disclosed |
| WO-2020143653-A1 | PREPARATION METHOD FOR GLUCOPYRANOSYL DERIVATIVE AND INTERMEDIATE THEREOF | 广东东阳光药业有限公司 | 2020-07-16 | — | — | WO | disclosed |
| EP-2292224-B1 | Derivatives of lactiosole for preventing or treating diabetes | SYMRISE AG (DE) | 2018-03-07 | — | — | EP | disclosed |
| US-8592621-B2 | Precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease | SYMRISE AG (DE) | 2013-11-26 | — | — | US | disclosed |
| US-8105978-B2 | Thermal transfer ink sheet, ink cartridge, coating composition for dye layer of thermal transfer ink sheet, and thermal transfer recording method | FUJIFILM CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| EP-2292224-A1 | Precursor compounds of sweet receptor antagonists for preventing or treating diabetes | Symrise AG (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | SYMRISE GMBH CO. KG (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20100248390-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING LIGANDS OF ODORANT RECEPTORS | DUKE UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20080241434-A1 | THERMAL TRANSFER INK SHEET, INK CARTRIDGE, COATING COMPOSITION FOR DYE LAYER OF THERMAL TRANSFER INK SHEET, AND THERMAL TRANSFER RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242464-A1 | METHOD FOR CONVERSION OF DIOLS TO OLEFIN PRODUCTS | DUOX1, HMOX1, HAO2 | MEN1 1294/4885CYP2C19 603/4885KMT2A 2775/4885 |
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | TAS1R2, TAS2R5, TAS2R1 | MEN1 1488/4885CYP2C19 3693/4885KMT2A 2910/4885 |
| US-11780787-B2 | Method for conversion of diols to olefin products | DUOX1, HMOX1, HAO2 | MEN1 1294/4885CYP2C19 603/4885KMT2A 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.